Insights and Analysis
Hogan Lovells 2024 M&A Outlook
01 May 2024
Our 10th annual M&A Year in Review features a 2024 M&A Outlook, which provides insights across the key topics that we expect will influence dealmaking in the months to come:...
Publications
News
The use of IVDs as CDx in pharmaceutical clinical trials
30 April 2024
The current European legislation for in vitro diagnostic medical devices (IVD) (Regulation 2017/746 or the IVDR) has created challenges not only for IVD manufacturers but also for...
News
2024 Life Sciences & Health Care Horizons
18 April 2024
While economic factors, including the high cost of capital, continue to keep our clients up at night, we also see signs of optimism in 2024. Against this fiscal backdrop, significant recent ...
News
Commission investigation into termination of pipeline drug: what next for R&D decision-making?
02 April 2024
The European Commission has opened a formal investigation into whether Zoetis, a US animal health company, has acted in breach of the abuse of dominance rules by terminating development of...
Insights and Analysis
Unsung regulatory approval vital to deal closing in acquiring businesses using radioactive materials
29 March 2024
Advancements in medical technology make healthcare and radiopharmaceutical companies attractive investment prospects. And we are seeing this interest in real time. However, acquiring...
Insights and Analysis
Key considerations for life sciences demerger deals in China
28 March 2024
This article discusses the most important legal and regulatory considerations for life sciences companies considering a demerger in China. The authors address the challenges and issues...
News
Spotlight on the U.S.: Panelists discuss navigating the IRA
04 March 2024
Hogan Lovells is hosting a special webinar series for Life Sciences and Health Care companies based in, or with commercial interests in, the Asia-Pacific (APAC) region. The series shares...
News
Revealing the covert economics of licensing and collaborations: Technology transfers
29 February 2024
Although upfront fees, milestones and royalties often take the spotlight in deal announcements in the life sciences sector, there exist numerous other cost allocation principles within...
News
Advances in Precision Medicine, the Future of Diagnostics, and FDA Priorities in an Election year
21 February 2024
Speaking at the J.P. Morgan Healthcare Conference this year, Hogan Lovells life sciences regulatory partners Lowell Zeta and Blake Wilson, were joined by Greenleaf Health’s Kalah...
